Proprietary & Confidential;
JPSHolding SCServing Life Sciences Industries Since 1993
Proprietary & Confidential;
Core Business Portfolio Management Products evaluation Products development Licensing-In and Out Expert Reports Regulatory dossiers development and
submission: medicines, food supplements, dietary foods for special medical purposes.
Drug Delivery Technology
Proprietary & Confidential;
Licensing-in (for Clients)
Paediatics drugs, medical food, food supplements
BCAA
Proprietary & Confidential;
Licensing-out AS 21: skin ulcers treatment (medical
device) AS 22: mucitis treatment (medical
device) Dualsetron®: Chemotherapy-Induced
Nausea and Vomiting treatment (Internal)
Biridone®: Bipolar disorders (Internal) Thixans® technology: thixotropic
formulation
MEDICAL For of skin injuries
AS-21
CE Authorization 0459
Proprietary & Confidential;
Proprietary & Confidential;
FIRST SPECIFIC TREATMENT AGAINST:
Bedsore (Superficial & Deep) Superficial & Deep Skin Injuries Pressure sore/Pressure ulcers Decubitus ulcers Diabetic skin ulcers
A NEW TRIPLE ACTION APPROACH
Proprietary & Confidential;
SALES New product: CE marking in August 2010 2 Trial launch in Finland January 2010 Sales Finland (Aktisor): 32 000 Launched in Austria 2010 – 10 000 units Israel- February 2011 Planned: Egypt, Middle East countries, India, Irak,
S. Africa, Australia,
Proprietary & Confidential;
AS 22 Specific treatment for Chemotherapy Induced oral mucositis (CIOM)
Proprietary & Confidential;
AS 22 OROCHEM® Mucitis following hemo and radiotherapy Colorless, odorless, sweet, viscous, 100
natural solution. Easy to apply, no side effects. Registered as a Class IIa medical device
due to its mechanical effects.
Proprietary & Confidential;
Dualsetron® Fixed-Dose combination for
Chemotherapy-Induced Nausea And Vomiting treatment.
Proprietary & Confidential;
Dualsetron
Proprietary & Confidential;
Biridone® Bipolar-disorders treament Patented formulation for once-day-
treatment
Proprietary & Confidential;
Development Status:
CR formulation completed Analytical development completed Stability studies Pilot Pk study completed MBDD protocol completed
Proprietary and Confidential: deNovelda Farmaceutica
THIXANS®: THE THIXOTROPIC DEVICE
Pure or formulated active ingredient or microparticulate dosage forms (pellets, beadlets, spheroids etc..) manufactured by usual pharmaceutical technologies are embedded into a Thixotropic Cushion ® either extemporaneously or regenerated by the microparticule itself.
Proprietary and Confidential: deNovelda Farmaceutica
DiffusionCoating
DiffusionCoating
MicrospheresMicrospheres
Thixotropic Cushion®Thixotropic Cushion®
EncapsulationEncapsulation
TechnologiesTechnologies
Thixotropic coatingThixotropic coating
DrugDrug